Dr Reddy's Labs to promote, distribute Sanofi paediatric, adult vaccine brands in India
These brands saw combined sales of approx. Rs 426 crores as per IQVIA MAT February 2024.
Hyderabad: Dr Reddy's Laboratories Ltd., a global pharmaceutical company, has announced that it has entered into an exclusive partnership with Sanofi Healthcare India Private Limited (“SHIPL”) to promote and distribute their vaccine brands across private markets in India.
About the portfolio:
| Brand | Label Indication |
| Hexaxim | Indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilusinfluenzae type b (Hib). |
| Pentaxim | Indicated for the active immunization of children against Diphtheria, Pertussis, Tetanus, Polio and against invasive infections due to Haemophilusinfluenzae type b bacterium (such as meningitis, septicaemia, etc.) in children from the age of 2 months or according to local recommendations. This vaccine does not protect against infections caused by other types of Haemophilusinfluenzae nor against meningitis due to other micro-organisms. |
| Tetraxim | Indicated in the joint prevention of diphtheria, tetanus, pertussis and poliomyelitis: for primary vaccination in infants from the age of 2 months, for booster vaccination, one year after primary vaccination during the second year of life, for booster vaccination between 5 and 13 years of age, according to official recommendations |
| Menactra | Indicated for active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y, and W-135. MENACTRA® is approved for use in individuals 9 months through 55 years of age |
| FluQuadri | FluQuadri is an inactivated quadrivalent influenza vaccine indicated for the prevention of influenza disease caused by influenza types A and B viruses contained in the vaccine. FluQuadri® is approved for use in persons 6 months of age and older. |
| Adacel | Indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis (whooping cough) as a single dose in persons aged 11 to 54 years. In accordance with local recommendations, ADACEL® may be considered as an alternative for the fifth dose of tetanus, diphtheria and acellular pertussis vaccine (DTaP) in children 4 to 6 years of age, concomitantly administered with Inactivated Poliomyelitis Vaccine (IPV), at separate sites to complete the vaccination series for this age, when indicated |
| Avaxim 80U | This vaccine is recommended for the prevention of the infection caused by the Hepatitis A virus in children aged from 12 months to 15 years inclusive |
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.